Trial Profile
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 01 Nov 2021 Primary endpoint (Median Progression Free Survival (mPFS)) has been met, according to Results published in the Cancer Immunology Immunotherapy.
- 01 Nov 2021 Results published in the Cancer Immunology Immunotherapy
- 13 Sep 2021 Status changed from active, no longer recruiting to completed.